CUPERTINO, Calif., Feb. 21, 2019 /PRNewswire/ -- DURECT
Corporation (Nasdaq: DRRX) today announced that James E. Brown, President and CEO, and
Mike Arenberg, Chief Financial
Officer, will be participating in the Berenberg NASH Day, taking
place Tuesday, February 26, 2019, at
Berenberg's New York City
offices. The format for the day includes an introductory
session, a presentation by Dr. Raymond
Chung of Harvard Medical School,
a five minute presentation by DURECT management and other attending
companies, and then one-on-one/small group meetings with companies
and with key opinion leaders (Dr. Amon
Asgharpour and Dr. Elliot
Goodman of Mount Sinai, and
Dr. Utpal Pajvani of Columbia
University Medical Center). Institutional investors
and analysts that are attending the conference may request
one-on-one meetings with DURECT management through the conference
coordinators.
About DURECT Corporation
DURECT is a biopharmaceutical
company actively developing therapeutics based on its Epigenetic
Regulator Program and proprietary drug delivery platforms.
DUR‑928, a new chemical entity in Phase 2 development, is the lead
candidate in DURECT's Epigenetic Regulator Program. An
endogenous, orally bioavailable small molecule, DUR-928 has been
shown in preclinical studies to play an important regulatory role
in lipid homeostasis, inflammation, and cell survival. Human
applications may include chronic liver diseases such as
nonalcoholic steatohepatitis (NASH), acute organ injury such as
Alcoholic Hepatitis (AH) and acute kidney injury (AKI), and
inflammatory skin conditions such as psoriasis and atopic
dermatitis. DURECT's advanced oral and injectable delivery
technologies are designed to enable new indications and enhanced
attributes for small-molecule and biologic drugs. Late stage
product candidates in this category include POSIMIR®
(bupivacaine extended-release solution), an investigational
locally-acting, non-opioid analgesic intended to provide up to 3
days of continuous pain relief after surgery, and
ORADUR®-Methylphenidate ER Capsules, approved in
Taiwan as Methydur Sustained
Release Capsules, where it is indicated for the treatment of
attention deficit hyperactivity disorder (ADHD). In addition,
for the assignment of certain patent rights, DURECT will receive
single digit sales-based earn-out payments from U.S. net sales of
Indivior's PERSERIS™ (risperidone) drug for
schizophrenia, which was approved in July 2018. For more
information, please visit www.durect.com.
NOTE: ORADUR®, POSIMIR® and
SABER® are trademarks of DURECT Corporation.
Other referenced trademarks belong to their respective
owners. DUR-928 and POSIMIR are drug candidates under
development and have not been approved for commercialization by the
U.S. Food and Drug Administration or other health authorities.
DURECT Forward-Looking Statement
The statements in this press release regarding the potential
benefits and uses of drug candidates, including the potential
earn-out payments receivable from Indivior, as well as the
potential use of POSIMIR to treat post-surgical pain, and the
potential use of DUR-928 to treat Alcoholic Hepatitis, hepatic and
renal diseases such as nonalcoholic steatohepatitis (NASH) and
Primary Sclerosing Cholangitis (PSC), and inflammatory skin
conditions such as psoriasis and atopic dermatitis are
forward-looking statements involving risks and uncertainties that
can cause actual results to differ materially from those in such
forward-looking statements. Potential risks and uncertainties
include, but are not limited to, the risks that PERSERIS will not
obtain market acceptance and meaningful sales, as well as possible
adverse events associated with the use of PERSERIS, POSIMIR and
DUR-928, delays and costs due to additional work or other
requirements imposed by regulatory agencies for continued
development, approval or sale of POSIMIR and DUR-928, and the
possibility that studies of DUR-928 will not replicate results from
earlier preclinical or clinical trials. Further information
regarding risks related to DUR-928 and POSIMIR and other risks
related to DURECT is included in DURECT's Form 10-Q filed on
November 5, 2018 under the heading
"Risk Factors."
View original
content:http://www.prnewswire.com/news-releases/durect-corporation-to-participate-in-the-berenberg-nash-day-300799047.html
SOURCE DURECT Corporation